All News
Does Evusheld shield people living with rheumatic diseases?
While COVID vaccination and subsequent booster remain the cornerstone, pre-exposure prophylaxis such as Evusheld (tixagevimab and cilgavimab) has been approved by FDA in December 2021 and EMA in March 2022 for people immunocompromised either due to a medical condition or receiving treatment with immunosuppressants and may not mount an adequate immune response to COVID vaccination. How does this therapy fare in RMD patients?
Read Article
Pan et al 11beta-hydroxysteroid dehydrogenase inhibitor SPI-62 mitigates glucocorticoid toxicity in mouse model. Human trial in PMR ongoing. @RheumNow #ACR22 Abstr#1549 https://t.co/t74Hazll9H https://t.co/4425RUwIz4
Richard Conway RichardPAConway ( View Tweet)
Mepolizumab assoc'd w/ clinical benefits in EGPA, including in patients w/ and w/o a vasculitic phenotype. Abs 1074 #ACR22 @RheumNow https://t.co/VCGhGaci8b https://t.co/OV8A1vsx1G
Dr. Rachel Tate uptoTate ( View Tweet)
Filho et al. Retrospective Brazilian study. ADA vs LEF in Takayasu arteritis. Comparable renission, relapses, steroid dose, ESR, CRP, imaging over median 15 weeks. More AEs in LEF but non-severe. @RheumNow #ACR22 Abstr#1553 https://t.co/499dUNmpUD https://t.co/AEk5cG7dc4
Richard Conway RichardPAConway ( View Tweet)
Juge @Juge_P_A @PhilippeDieude et al. RA-ILD patients have shorter telomere length than RA without ILD. RA-ILD similar telomere length to IPF. OR 0.54 for RA-ILD. Assoc with FVC%pred also. @RheumNow #ACR22 Abstr#1122 https://t.co/H5A7unpjjB https://t.co/IjvHmupykM
Richard Conway RichardPAConway ( View Tweet)
Del-Río-Guerrero et al. Sphygmomanometry-induced allodynia for fibromyalgia detection. 62% sensitivity and 84% specificity. Much pain = 23% sensitivity and 96% specificity. Only seems to apply in female patients. @RheumNow #ACR22 Abstr#1225 https://t.co/zCHfmvwOcn https://t.co/tjBBny0WSR
Richard Conway RichardPAConway ( View Tweet)
Abstr 1255 Do Rheumatologists overcall sacroiliitis on imaging in axSpA?
Compared to central readers:
-Agreement w/ local readers = 87% agreement (X-Rays); 74.5% (MRIs)
- Agreement w/ Academic rheumatologists was greater vs community rheumatologists
#ACR22 @RheumNow https://t.co/j2vFoKA3n0
Akhil Sood MD AkhilSoodMD ( View Tweet)
Study by Dr EPapachristodoulou on
features of #lupus pts w/ LAD: myo/pericarditis, cytopenias, nephritis,⬆️markers
Those w/LN biopsy: reactive(66.7%) vs. necrotizing(33.3%) pattern
👉Pts w/ necrotizing pattern: unexplained fevers, sicca& malar rash.
#ACR22 @RheumNow ABST1443 https://t.co/J4aMRnYk8N
sheila RHEUMarampa ( View Tweet)
Avacopan's efficacy and safety profiles support use in AAV in Abs 1077 #ACR22 @RheumNow https://t.co/Zp05ofTgFP https://t.co/zA2sIEfYCS
Dr. Rachel Tate uptoTate ( View Tweet)
Join us for our daily topic panels--we'll be live on Twitter, LinkedIn, FB and YouTube OR sign up directly below. #ACR22
https://t.co/Oql4iv6RyO https://t.co/S4t7ucliUF
Links:
Dr. John Cush RheumNow ( View Tweet)
Much gusto for GUSTO: Efficacy of Tocilizumab Monotherapy for GCA
Dr. Richard Conway discusses abstract 0470 - being presented at the #ACR22 meeting.
https://t.co/btztbYWjq1 https://t.co/hrpZhIRLKO
Links:
Dr. John Cush RheumNow ( View Tweet)
Ab1115 #ACR22 Rx Co-Pay affects Rx Adherence in SLE
Higher copays associated w/:
💊39% lower odds of HCQ adherence
💊56% lower AZA adherence
💊32% lower MMF adherence
Need better $$ and transparency into costs. Screen for determinants of health affecting affordability!
@Rheumnow https://t.co/1NdBb3GLzL
Eric Dein ericdeinmd ( View Tweet)
Abs 0829 at #ACR22 finds AOSD more commonly affects caucasian females. Also notes abnormal labs include elevated inflammatory markers, leukocytosis, and anemia. @RheumNow https://t.co/1Nr8C5dX3G
Dr. Rachel Tate uptoTate ( View Tweet)
There's a lot of Scleroderma-like fibrosing skin disorders!
#ACR22 @RheumNow #RheumTwitter @rheumarhyme https://t.co/W1AEtfeKZc
sheila RHEUMarampa ( View Tweet)
Serum AMH reduced in adolescents w/ rheumatic disease compared to menstrual-age matched, healthy controls. UCTD and SLE higher disease activity assoc'd w/ dec AMH levels, suggesting dz activity and dz may affect ovarian reserve. Abs 0942 #ACR22 @RheumNow https://t.co/xSZ85ipFSD https://t.co/tsaWBdrQcb
Dr. Rachel Tate uptoTate ( View Tweet)
Excllent plenary, medication copay modifies treatment adherence in SLE
>$10 copay reduced adherence for HCQ (39%), AZA (56%), MMF (32%)
Easy to imagine that all our innovation cannot overcome access & barriers
Should be priority to fix
#ACR22 @RheumNow #ACRBest Abstr#1115 https://t.co/BPfr9mCVgy
Mike Putman EBRheum ( View Tweet)
Congenital ❤️ Block in Ro/La pregnancies
Abst#0957
👉1st echo @ mean 20wk
👉CHB 3/47- all on 1st echo
👉 1 reversed 3rd ➡️ 1st AVB post dexamethasone
🔥Key messages🔥
🤰serial echo should start @ 16-18wk gestation
👶 early detection ⬆️ outcomes
#ACR22 @RheumNow
Patricia Harkins DrTrishHarkins ( View Tweet)
Combined estrogen-progestin contraception in SLE patients with positive aPL conferred an increased risk of thrombosis relative to progestin-only contraception. Abs 0943 #ACR22 @RheumNow https://t.co/B2Wmhlz6at https://t.co/YlvqoYY8FN
Dr. Rachel Tate uptoTate ( View Tweet)
🖊️Eosinophilic fasciitis is not assoc. w/ RP
🖊️On biopsy, extends to SC fat and fascia
🖊️CS are 1st line tx; remission is the rule but takes a while so SLOWLY taper steroids
#ACR22 @Rheumnow #RheumTwitter https://t.co/Z26Gim9JUW
sheila RHEUMarampa ( View Tweet)
Use of pregnancy-compatible medication and control of disease activity with lower glucocorticoid doses in PM/DM pregnancies may be important to achieve good pregnancy outcomes. Abs 0952 #ACR22 @RheumNow https://t.co/LMfebb4GE1 https://t.co/0gYG245BXV
Dr. Rachel Tate uptoTate ( View Tweet)